BREAKING
PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap 16 minutes ago Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings 24 minutes ago USA Rare Earth, Inc. (USAR) Reports Q4 Earnings 27 minutes ago Bicara Therapeutics 2025 Financial Update 40 minutes ago PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings 54 minutes ago Neumora Therapeutics 2025 Financial Update 1 hour ago Americas Gold and Silver Corporation (USAS) Misses FY2025 EPS Estimates by 425.0% 1 hour ago CBAK Energy Technology, Inc. (CBAT) Reports FY2025 Earnings 2 hours ago Reviva Pharmaceuticals 2025 Financial Review 2 hours ago Southland Holdings, Inc. (SLND) Q4 Earnings: Misses on EPS, Revenue Recap 3 days ago PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap 16 minutes ago Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings 24 minutes ago USA Rare Earth, Inc. (USAR) Reports Q4 Earnings 27 minutes ago Bicara Therapeutics 2025 Financial Update 40 minutes ago PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings 54 minutes ago Neumora Therapeutics 2025 Financial Update 1 hour ago Americas Gold and Silver Corporation (USAS) Misses FY2025 EPS Estimates by 425.0% 1 hour ago CBAK Energy Technology, Inc. (CBAT) Reports FY2025 Earnings 2 hours ago Reviva Pharmaceuticals 2025 Financial Review 2 hours ago Southland Holdings, Inc. (SLND) Q4 Earnings: Misses on EPS, Revenue Recap 3 days ago
ADVERTISEMENT
Breaking News

Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings

Unicycive Therapeutics, Inc. (UNCY) posted Q4 2025 basic and diluted EPS of -$1.67.

March 30, 2026 1 min read

Unicycive Therapeutics, Inc. (UNCY) posted Q4 2025 basic and diluted EPS of -$1.67.

UNCYUNCY|EPS -$1.67|Net Loss $26.6M

Unicycive Therapeutics, Inc. (UNCY) posted FY 2025 basic and diluted EPS of -$1.67.

Unicycive Therapeutics, Inc. is a Biotechnology company. Bottom line showed a net loss of $26.6M.

Wall Street consensus stands at 10 buy, 1 hold, 0 sell.

This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.

ADVERTISEMENT